BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH FIRST-LINE BEV plus CT (ML18147): EFFICACY AND SAFETY ANALYSES BY OXALIPLATIN VS IRINOTECAN-BASED CT

被引：0
|
作者：
Osterlund, P. [1 ]
Alonso-Orduna, V. [2 ]
Schlichting, C. [3 ]
Andre, T. [4 ,5 ]
Sastre, J. [6 ]
Greil, R. [7 ]
Kubicka, S. [8 ]
Reyes-Rivera, I. [9 ]
McCall, B. [10 ]
Van Cutsem, E. J. D. [11 ]
机构：
[1] Univ Helsinki, Cent Hosp, Helsinki, Finland
[2] Hosp Univ Miguel Servet, Med Oncol Serv, Zaragoza, Spain
[3] Diakoniekrankenhaus Rotenburg GmbH, Chirurg Klin 1, Rotenburg, Germany
[4] Hop St Antoine, F-75571 Paris, France
[5] Univ Paris 06, Paris, France
[6] Serv Oncol Med HC, Madrid, Spain
[7] III Med Univ Klin Salzburg, Ctr Oncol, Salzburg, Austria
[8] Canc Ctr Reutlingen, Reutlingen, Germany
[9] Genentech Inc, Stat, San Francisco, CA 94080 USA
[10] Genentech Inc, Oncol, Prod Dev, San Francisco, CA 94080 USA
[11] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195 / 195
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF TREATMENT WITH BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV plus CT: AGE SUBGROUP ANALYSIS FROM A RANDOMISED PHASE III INTERGROUP STUDY (ML18147)
    Bouche, O.
    Steffens, C.
    Andre, T.
    Bennouna, J.
    Sastre, J.
    Osterlund, P.
    von Moos, R.
    Reyes-Rivera, I.
    Sersch, M. A.
    Arnold, D.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 190 - 191
  • [2] BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV-BASED THERAPY: OVERALL SURVIVAL SUBGROUP FINDINGS FROM ML18147
    Vieitez de Prado, J. M.
    Borg, C.
    Arnold, D.
    Greil, R.
    Van Cutsem, E. J. D.
    von Moos, R.
    Bennouna, J.
    Reyes-Rivera, I.
    Bendahmane, B.
    Kubicka, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 193 - 193
  • [3] Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV plus chemotherapy (CT): Biomarker findings from ML18147.
    Kubicka, Stefan
    Von Moos, Roger
    Greil, Richard
    Sastre, Javier
    Osterlund, Pia J.
    Arnold, Dirk
    Andre, Thierry
    Van Cutsem, Eric
    Mueller, Thomas
    Reyes-Rivera, Irmarie
    Bennouna, Jaafar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [4] Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.
    Kubicka, Stefan
    Greil, Richard
    Andre, Thierry
    Bennouna, Jaafar
    Sastre, Javier
    Van Cutsem, Eric
    Von Moos, Roger
    Osterlund, Pia J.
    Hegde, Priti
    Sersch, Martina A.
    Osborne, Stuart
    Hermann, Frank
    Arnold, Dirk
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).
    Arnold, Dirk
    Andre, Thierry
    Bennouna, Jaafar
    Sastre, Javier
    Osterlund, Pia J.
    Greil, Richard
    Van Cutsem, Eric
    Von Moos, Roger
    Reyes-Rivera, Irmarie
    Bendahmane, Belguendouz
    Kubicka, Stefan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966
    Cassidy, J.
    Cunningham, D.
    Berry, S. R.
    Rivera, F.
    Clarke, S. J.
    Kretzschmar, A.
    Diaz-Rubio, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
    Kubicka, S.
    Greil, R.
    Andre, T.
    Bennouna, J.
    Sastre, J.
    Van Cutsem, E.
    von Moos, R.
    Oesterlund, P.
    Reyes-Rivera, I.
    Mueller, T.
    Makrutzki, M.
    Arnold, D.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (09) : 2342 - 2349
  • [8] ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.
    Wainberg, Zev A.
    Wang, Lan
    Yue, Huibin
    Motwani, Monica
    Kasichayanula, Sreeneeranj
    Blaney, Martha Elizabeth
    Naumovski, Louie
    Strickler, John H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC).
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Antoniotti, Carlotta
    Marmorino, Federica
    Zoratto, Federica
    Bergamo, Francesca
    Brunetti, Isa Maura
    Pfanner, Elisabetta
    Masi, Gianluca
    Genovesi, Dario
    Filidei, Elena
    Giorgetti, Assuero
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomised phase III intergroup study initiated by the AIO and AGMT (ML18147)
    Greil, R.
    Arnold, D.
    Hegewisch-Becker, S.
    Freier, W.
    Steffens, C. -C.
    Bertram, M.
    Schlichting, C.
    Andel, J.
    Taylor, M.
    Makrutzki, M.
    Kubicka, S.
    [J]. ONKOLOGIE, 2012, 35 : 254 - 254
12345